Bristol-Myers (BMY - Get Report) said the deal, which if first unveiled in early January, would mean give combined companies number one positions in oncology and cardiovascular drug sales, with a top five standing in immunology and inflammation and nine currency products with over $1 billion in sales. It also sees earnings and revenues growing every year through 2025 and an 8% improvement in margins from its 2018 base.

Starboard, for its part, opposes the deal, arguing Celgene (CELG - Get Report) is a company facing a "massive patent cliff" that will force it to replace some 60% of its revenues over the next seven years. It also thinks Celgene's drug pipeline is "extremely risky" and says the takeover proposal was too hastily put together.

Here's why Jim Cramer is a fan of the deal and why he believes that shareholders should vote for the deal, not against it. 

Related. Tilray Has Rebased and Looks Poised to Rally Again - Consider Buying Strength

Will You Have Enough Money to Retire? Want to learn about retirement planning from some of the nation's top experts? Join TheStreet's Robert "Mr. Retirement" Powell live in New York on April 6 for our Retirement Strategies Symposium. For a limited time, tickets are available for $99 for this full-day event. Check out the agenda, learn about the speakers and sign up here.

Watch Jim Cramer's Daily NYSE Show and Replays Below